Variables | Unweighted characteristics (before IPTW) | Characteristics after weighting for IPTW | ||||||
---|---|---|---|---|---|---|---|---|
Apixaban (n = 4471) |
Dabigatran (n = 3246) |
Rivaroxaban (n = 3299) |
Warfarin (n = 10,338) |
Apixaban (n = 4471) |
Dabigatran (n = 3246) |
Rivaroxaban (n = 3299) |
Warfarin (n = 1038) |
|
Age (years), mean | 69.9 | 65.7 | 66.7 | 66.5 | 67.3 | 67.2 | 67.3 | 67.2 |
Women, % | 1 | 1 | 1 | 1.1 | 8 | 7 | 10 | 11 |
Years | ||||||||
2013-2014, % | 1.4 | 26.2 | 9.9 | 45.0 | 22.6 | 29.0 | 26.9 | 28.9 |
2015-2016, % | 47.3 | 50.1 | 52.5 | 39.8 | 46.2 | 46.8 | 45.2 | 46.3 |
2017-2018, % | 51.3 | 23.7 | 37.6 | 38.6 | 31.1 | 24.2 | 27.9 | 24.7 |
Race, % | ||||||||
White | 81.2 | 81.5 | 80.3 | 80.8 | 79.5 | 81.0 | 80.3 | 81.0 |
Black | 9.9 | 9.6 | 11.0 | 10.8 | 11.6 | 10.1 | 10.3 | 10.6 |
Hispanic | 1.8 | 2.1 | 2.0 | 1.9 | 2.6 | 1.9 | 2.1 | 1.9 |
Other | 1.6 | 1.8 | 1.8 | 1.6 | 1.6 | 2.0 | 1.9 | 1.6 |
History of bleeding, % | ||||||||
GI bleeding | 3.7 | 3.3 | 4.0 | 6.2 | 5.8 | 4.8 | 5.2 | 5.1 |
ICH | 0.2 | 0.1 | 0.2 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 |
Any major bleeding | 8.7 | 7.2 | 7.8 | 11.6 | 11.2 | 9.5 | 10.5 | 10.2 |
Days since AF diagnosis | 484 | 446 | 465 | 371 | 420.3 | 419.2 | 426.7 | 422.5 |